Table 1.
Characteristics of 275 Hepatocellular Carcinoma (HCC) Patients Who Underwent Drug-Eluting Beads Transarterial Chemoembolization (DEB-TACE) Treatment
| Parameters | Patients (N = 275) |
|---|---|
| Age (years) | 58.7 ± 11.5 |
| Gender (male/female) | 228/47 |
| History of HB (n/%) | 228 (82.9) |
| History of drink (n/%) | 130 (47.3) |
| History of cirrhosis (n/%) | 165 (60.0) |
| Tumor distribution | |
| Multifocal disease (n/%) | 180 (65.5) |
| Unifocal disease (n/%) | 95 (34.5) |
| Tumor location | |
| Left liver (n/%) | 42 (15.3) |
| Right liver (n/%) | 144 (52.4) |
| Bilobar (n/%) | 89 (32.4) |
| Largest nodule size (cm) | 4.8 (2.8–8.6) |
| Portal vein invasion (n/%) | 82 (29.8) |
| Hepatic vein invasion (n/%) | 37 (13.5) |
| ECOG performance status | |
| 0 (n/%) | 172 (62.5) |
| 1 (n/%) | 83 (30.2) |
| 2 (n/%) | 14 (5.1) |
| 3 (n/%) | 6 (2.2) |
| Child–Pugh stage | |
| A (n/%) | 228 (82.9) |
| B (n/%) | 45 (16.4) |
| C (n/%) | 2 (0.7) |
| BCLC stage | |
| 0 (n/%) | 1 (0.4) |
| A (n/%) | 67 (24.4) |
| B (n/%) | 108 (39.3) |
| C (n/%) | 98 (35.6) |
| D (n/%) | 1 (0.4) |
| Cycles of DEB-TACE treatment | |
| One cycle (n/%) | 227 (82.5) |
| Two or more cycles (n/%) | 48 (17.5) |
| CBC | |
| WBC (×109 cell/L) | 5.0 (3.6–6.3) |
| RBC (×1012 cell/L) | 4.3 (3.9–4.8) |
| ANC% | 61.0 (52.1–68.9) |
| Hb (g/L) | 129.0 (107.0–146.5) |
| PLT (×109 cell/L) | 112.0 (70.5–164.5) |
| Liver function | |
| ALB (g/L) | 39.1 (35.2–42.9) |
| TP (g/L) | 68.6 (64.3–73.3) |
| TBIL (μmol/L) | 16.0 (11.5–23.0) |
| TBA (I/L) | 12.0 (6.7–26.9) |
| ALT (μ/L) | 28.0 (20.0–42.0) |
| AST (μ/L) | 37.0 (27.0–56.0) |
| ALP (μ/L) | 117.0 (85.0–162.0) |
| Kidney function | |
| BCr (μmol/L) | 72.0 (62.0–81.0) |
| BUN (mmol/L) | 4.9 (4.0–6.2) |
| Tumor markers | |
| AFP (μg/L) | 59.2 (7.4–1280.9) |
| CEA (μg/L) | 2.7 (1.8–4.3) |
| CA19-9 (kU/L) | 13.7 (6.5–28.8) |
| Previous treatments | |
| cTACE (n/%) | 118 (42.9) |
| Surgery (n/%) | 68 (24.7) |
| Systematic chemotherapy (n/%) | 8 (2.9) |
| Radiofrequency ablation (n/%) | 36 (13.1) |
| Targeted therapy (n/%) | 8 (2.9) |
| Combination of ordinary embolization agent | 100 (36.4) |
| Treatments post-DEB-TACE | |
| No treatment (n/%) | 206 (74.9) |
| Radiofrequency ablation (n/%) | 1 (0.4) |
| Sorafenib (n/%) | 4 (1.4) |
| Apatinib (n/%) | 1 (0.4) |
| Antiviral therapy (n/%) | 21 (7.7) |
| Traditional Chinese medicine (n/%) | 24 (8.7) |
| Sorafenib combined with antiviral therapy (n/%) | 1 (0.4) |
| Antiviral therapy combined with traditional Chinese medicine (n/%) | 8 (2.9) |
| Chemotherapeutics combined with traditional Chinese medicine (n/%) | 1 (0.4) |
| Other (n/%) | 8 (2.9) |
Data are presented as mean ± standard deviation, median (25th–75th), or count (%). HCC, hepatocellular carcinoma; HB, hepatitis B; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; DEB-TACE, drug-eluting bead transarterial chemoembolization; WBC, white blood cell; RBC, red blood cell; ANC, absolute neutrophil count; Hb, hemoglobin; PLT, platelet; ALB, albumin; TP, total protein; TBIL, total bilirubin; TBA, total bile acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; BCr, blood creatinine; BUN, blood urea nitrogen; AFP, α-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen19-9; cTACE, conventional transarterial chemoembolization.